Fate Therapeutics, Inc. (FATE)
2.08
-0.09
(-4.15%)
USD |
NASDAQ |
Oct 30, 16:00
2.09
+0.01
(+0.48%)
After-Hours: 20:00
Fate Therapeutics Cash from Operations (Quarterly) : -23.43M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -23.43M |
| March 31, 2026 | -30.82M |
| December 31, 2025 | -23.31M |
| September 30, 2025 | -24.37M |
| June 30, 2025 | -24.59M |
| March 31, 2025 | -33.81M |
| December 31, 2024 | -27.80M |
| September 30, 2024 | -29.42M |
| June 30, 2024 | -32.31M |
| March 31, 2024 | -33.35M |
| December 31, 2023 | -36.64M |
| September 30, 2023 | -38.27M |
| June 30, 2023 | -28.49M |
| March 31, 2023 | -28.86M |
| December 31, 2022 | -75.39M |
| September 30, 2022 | -55.05M |
| June 30, 2022 | -53.16M |
| March 31, 2022 | -64.61M |
| December 31, 2021 | -70.29M |
| September 30, 2021 | -33.38M |
| June 30, 2021 | -32.11M |
| March 31, 2021 | -27.10M |
| December 31, 2020 | -20.66M |
| September 30, 2020 | -30.73M |
| June 30, 2020 | 38.84M |
| Date | Value |
|---|---|
| March 31, 2020 | -26.67M |
| December 31, 2019 | -25.54M |
| September 30, 2019 | -19.84M |
| June 30, 2019 | -20.31M |
| March 31, 2019 | -17.49M |
| December 31, 2018 | -11.02M |
| September 30, 2018 | -3.556M |
| June 30, 2018 | -11.52M |
| March 31, 2018 | -12.55M |
| December 31, 2017 | -10.72M |
| September 30, 2017 | -9.857M |
| June 30, 2017 | -8.872M |
| March 31, 2017 | -7.455M |
| December 31, 2016 | -7.551M |
| September 30, 2016 | -7.516M |
| June 30, 2016 | -7.504M |
| March 31, 2016 | -7.252M |
| December 31, 2015 | -6.97M |
| September 30, 2015 | -7.131M |
| June 30, 2015 | 2.079M |
| March 31, 2015 | -6.375M |
| December 31, 2014 | -6.154M |
| September 30, 2014 | -5.521M |
| June 30, 2014 | -5.489M |
| March 31, 2014 | -5.255M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| AVITA Medical, Inc. | -3.630M |
| Agenus, Inc. | -31.20M |
| Amgen, Inc. | 4.002B |
| Anika Therapeutics, Inc. | -0.684M |
| BioCryst Pharmaceuticals, Inc. | 103.98M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 14.56M |
| Cash from Financing (Quarterly) | 1.736M |
| Free Cash Flow | -105.66M |
| Free Cash Flow Per Share (Quarterly) | -0.1953 |
| Free Cash Flow to Equity (Quarterly) | -22.40M |
| Free Cash Flow to Firm (Quarterly) | -23.51M |
| Free Cash Flow Yield | -42.45% |